“Efficacy and Safety of Tislelizumab Plus Lenvatinib as First-Line Treatment in Patients with Unresectable Hepatocellular Carcinoma ” (2024) Medical Forum Monthly, 35(6). Available at: https://medicalforummonthly.com/index.php/mfm/article/view/4698 (Accessed: 1 February 2026).